Trials / Completed
CompletedNCT00768469
Study Evaluating Safety And Tolerability, Solid Tumor
A Phase 1 Study Of Neratinib (HKI-272) In Combination With Paclitaxel In Subjects With Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Puma Biotechnology, Inc. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, phase 1 study of ascending multiple oral doses of HKI-272 in combination with paclitaxel.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Neratinib | Administered orally, continuous, once daily. |
| DRUG | Paclitaxel | Administered IV, on days 1, 8, 15 of 28 day cycle. |
Timeline
- Start date
- 2008-10-01
- Primary completion
- 2011-01-01
- Completion
- 2011-01-01
- First posted
- 2008-10-08
- Last updated
- 2018-11-19
- Results posted
- 2018-11-19
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00768469. Inclusion in this directory is not an endorsement.